🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "major milestone" in the fight against superbug strains of the pathogen, according to scientists.

A Global Challenge

Cases of gonorrhoea are escalating worldwide, with figures suggesting in excess of 82 million instances per year. Particularly high rates are observed in the African continent and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely development in the reality of growing infection rates, escalating drug resistance and the highly restricted available drugs at this time.”

Health officials are increasingly worried about the rise in drug-resistant strains. The WHO has listed it as a "high-priority threat". Ongoing monitoring showed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Receive Approval

Zoliflodacin, also known as a brand name, was cleared by the US Food and Drug Administration in mid-December for treating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Scientists believe that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This medication, which is employed against UTIs, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin stemmed from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to see it through.

“This approval marks a significant shift in the management of highly resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Research Study Results and Global Access

Based on results detailed in a major medical journal, zoliflodacin cured more than 90% of genital gonorrhoea infections. This places it at an similar efficacy with the current standard treatment, which involves a dual-drug approach. The trial enrolled over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the authority to register and commercialise the drug in numerous regions with limited resources.

Clinicians directly involved have expressed hope. Access to a single-dose, oral treatment like this is seen as a "critical tool" for gonorrhoea control. This is viewed as crucial to lessen the impact of the infection for individuals and to halt the transmission of extremely resistant gonorrhoea worldwide.